Implanet S.A. Rights represent a category of financial instruments known as subscription rights, which are typically issued in connection with a capital increase by Implanet S.A., a French medical technology company specializing in implants for orthopedic surgery. These rights grant existing shareholders the opportunity to purchase new shares of Implanet S.A. at a predetermined price, usually on a pro-rata basis, before shares are offered to the broader market. The primary function of Implanet S.A. Rights is to enable current investors to maintain their proportional ownership during capital-raising events, thereby limiting dilution. These instruments play a crucial role during equity financings, particularly in supporting the company’s ability to attract additional capital while offering shareholders a preferential means to participate. Implanet S.A. operates principally in the orthopedic and spine surgery sectors, known for innovative solutions such as the JAZZ® and MADISON product ranges. By issuing rights, Implanet S.A. can efficiently fund strategic initiatives or strengthen its balance sheet while preserving shareholder value and engagement in a competitive medical technology market.